Skip to Main Content
Phase II

Exploring Metformin's Impact on Kidney Health in FSGS Patients

  • Study HIC#:2000035723
  • Last Updated:03/19/2024

We're exploring how well and safely Metformin (MF) can work alongside other treatments for FSGS, a kidney disease. We're also looking into how FSGS reacts at a cellular level to Metformin, which could help design future trials and understand how targeting specific cellular processes might treat FSGS.

    Contact Us

    For more information about this study, including how to volunteer, contact:

    Gabriel Barsotti

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

    Trial Purpose and Description

    We're exploring how well and safely Metformin (MF) can work alongside other treatments for FSGS, a kidney disease. We're also looking into how FSGS reacts at a cellular level to Metformin, which could help design future trials and understand how targeting specific cellular processes might treat FSGS.

    Eligibility Criteria

    Inclusion criteria:

    1. Participants must be 18 years of age or older, but =or <80 years of age at the time of the informed consent
    2. Kidney Biopsy confirming FSGS
    3. Therapeutic plan by treating physician for treatment using glucocorticoids.
    4. eGFR of >30 ml/min/m 2

    Exclusion criteria:

    1. Liver disease
    2. Diabetes mellitus diagnosis at the time of biopsy or need for oral hypoglycemic agents/insulin
    3. Kidney biopsy with non-FSGS glomerulonephritis or secondary FSGS.
    4. Diagnosis of Dementia
    5. Allergy or sensitivity to Metformin
    6. Platelet count <100,000/ml; INR >1.5; bleeding diathesis or blood thinner use contraindicating biopsy.
    7. Current pregnancy or desire to become pregnant during the study period
    8. Currently enrolled in (or completed within the past 30 days) a study of an investigational drug or device

    Principal Investigator

    For more information about this study, including how to volunteer, contact:

    Gabriel Barsotti